Bladder Cancer Therapeutics Market Overview
Bladder cancer is aroused due to malignancy of urinary bladder lining with epithelial cells. Bladder is an organ present at lower part of abdomen and stores urine. Over developing of these epithelial cells results in blabber cancer and it can be of many types such as transitional cell carcinoma, squamous cell carcinoma, and adenocarcinoma. At present number of therapies have been evolved for the management of bladder cancers include chemotherapies, immune therapies, surgeries, radiation therapies, and other therapies.
Growing number of innovative treatments (such as targeted therapies & biological treatments), rising awareness among people about bladder cancer therapies, and increasing healthcare expenditure are driving the growth of global bladder cancer therapeutics market. In addition, growing research in the development of innovative bladder cancer therapies and presence of pipeline therapeutics are further propelling the growth of global bladder cancer therapeutics market. However, high cost of bladder cancer therapies, limited adoption of advanced cancer therapies, stringent regulatory policies, and poorly developed healthcare infrastructure are restraining the growth of global bladder cancer therapeutics market.
Bladder Cancer Therapeutics Market Forecast Report (2018-2023)
Global Bladder Cancer Therapeutics Market is expected to reach USD 305.13 million by 2023 from USD 240.22 million in 2018, growing at a CAGR of 4.9% during the forecast period 2018–2023.
Browse Report Brief and TOC @ https://www.marketdataforecast.com/market-reports/bladder-cancer-therapeutics-market-1149/
Bladder Cancer Therapeutics Market Segmentation
Global Bladder Cancer Therapeutics market is segmented based on type and treatment. Based on type, the market is further sub-segmented as Transitional Cell Bladder Cancer, Non Muscle Invasive/Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Adenocarcinoma of the Bladder, and Rare Bladder Cancers. Based on treatment, the market is further segmented as Surgery, Chemotherapy, Immunotherapy, Radiation Therapy, and Intravesical Therapy.
On the basis of geographical region the global Bladder Cancer Therapeutics market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America commands the major market share of 41.0% of the global Bladder Cancer Therapeutics market in 2018, whereas Asia-Pacific is expected to grow at the highest CAGR of 5.68 % during the forecast period 2018–2023.
The major companies dominating this market for its products and services are
- Sanofi S.A. (France),
- Novartis AG (Switzerland),
- Pfizer Inc. (U.S.),
- GlaxoSmithKline plc (U.K.),
- Eli Lilly and Company (U.S.),
- AstraZeneca plc (U.K.),
- Bristol-Myers Squibb (U.S.),
- F. Hoffmann-La Roche Ltd. (Switzerland),
- Celgene Corporation (U.S.).
Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients.
For more information:
Sales Manager at Market Data Forecast